1. Home
  2. NEPH vs SLGL Comparison

NEPH vs SLGL Comparison

Compare NEPH & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.96

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

N/A

Current Price

$42.00

Market Cap

117.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEPH
SLGL
Founded
1997
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.0M
117.8M
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
NEPH
SLGL
Price
$4.96
$42.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$50.00
AVG Volume (30 Days)
75.2K
15.3K
Earning Date
11-06-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$17,930,000.00
$18,970,000.00
Revenue This Year
$33.32
$121.82
Revenue Next Year
$12.27
N/A
P/E Ratio
$36.15
N/A
Revenue Growth
32.36
62.04
52 Week Low
$1.39
$4.02
52 Week High
$6.42
$52.26

Technical Indicators

Market Signals
Indicator
NEPH
SLGL
Relative Strength Index (RSI) 47.81 57.44
Support Level $4.83 $38.30
Resistance Level $5.97 $44.43
Average True Range (ATR) 0.62 3.59
MACD -0.04 0.02
Stochastic Oscillator 26.90 68.45

Price Performance

Historical Comparison
NEPH
SLGL

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Share on Social Networks: